TY - JOUR
T1 - Effect of Spironolactone on Kidney Function in Kidney Transplant Recipients (the SPIREN trial)
T2 - A Randomized Placebo-Controlled Clinical Trial
AU - Mortensen, Line A
AU - Jespersen, Bente
AU - Helligsoe, Anne Sophie L
AU - Tougaard, Birgitte
AU - Cibulskyte-Ninkovic, Donata
AU - Egfjord, Martin
AU - Boesby, Lene
AU - Marcussen, Niels
AU - Madsen, Kirsten
AU - Jensen, Boye L
AU - Petersen, Inge
AU - Bistrup, Claus
AU - Thiesson, Helle C
PY - 2024/6/1
Y1 - 2024/6/1
N2 - Key PointsSpironolactone is safe for kidney transplant patients.Spironolactone reduces kidney function by an acute effect, whereafter it remains stable.Spironolactone does not affect the progression of interstitial fibrosis in protocol biopsies.BackgroundLong-term kidney allograft survival is hampered by progressive interstitial fibrosis and tubular atrophy. The SPIREN trial tested the hypothesis that the mineralocorticoid receptor antagonist spironolactone stabilizes kidney function and attenuates glomerular barrier injury in kidney transplant patients treated with calcineurin inhibitors.MethodsWe conducted a randomized, placebo-controlled, double-blind clinical trial including 188 prevalent kidney transplant patients. Patients were randomized to spironolactone or placebo for 3 years. GFR was measured along with proteinuria and kidney fibrosis. The primary end point was change in measured GFR. Secondary outcomes were 24-hour proteinuria, kidney allograft fibrosis, and cardiovascular events. Measured GFRs, 24-hour proteinuria, and BP were determined yearly. Kidney biopsies were collected at baseline and after 2 years (n=48). Fibrosis was evaluated by quantitative stereology and classified according to Banff.ResultsThe groups were comparable at baseline except for slightly older allografts in the spironolactone group. Spironolactone reduced measured GFRs (up to -7.6 [95% confidence interval, -10.9 to -4.3] ml/min compared with placebo) independently of time since transplantation and BP with no effect on the kidney function curve over time and reduced 24-hour proteinuria after 1 year. There was no significant effect of spironolactone on the development of interstitial fibrosis.ConclusionsSpironolactone added to standard therapy for 3 years in kidney transplant patients did not improve kidney function, long-term proteinuria, or interstitial fibrosis.Clinical Trial registration numberNCT01602861.
AB - Key PointsSpironolactone is safe for kidney transplant patients.Spironolactone reduces kidney function by an acute effect, whereafter it remains stable.Spironolactone does not affect the progression of interstitial fibrosis in protocol biopsies.BackgroundLong-term kidney allograft survival is hampered by progressive interstitial fibrosis and tubular atrophy. The SPIREN trial tested the hypothesis that the mineralocorticoid receptor antagonist spironolactone stabilizes kidney function and attenuates glomerular barrier injury in kidney transplant patients treated with calcineurin inhibitors.MethodsWe conducted a randomized, placebo-controlled, double-blind clinical trial including 188 prevalent kidney transplant patients. Patients were randomized to spironolactone or placebo for 3 years. GFR was measured along with proteinuria and kidney fibrosis. The primary end point was change in measured GFR. Secondary outcomes were 24-hour proteinuria, kidney allograft fibrosis, and cardiovascular events. Measured GFRs, 24-hour proteinuria, and BP were determined yearly. Kidney biopsies were collected at baseline and after 2 years (n=48). Fibrosis was evaluated by quantitative stereology and classified according to Banff.ResultsThe groups were comparable at baseline except for slightly older allografts in the spironolactone group. Spironolactone reduced measured GFRs (up to -7.6 [95% confidence interval, -10.9 to -4.3] ml/min compared with placebo) independently of time since transplantation and BP with no effect on the kidney function curve over time and reduced 24-hour proteinuria after 1 year. There was no significant effect of spironolactone on the development of interstitial fibrosis.ConclusionsSpironolactone added to standard therapy for 3 years in kidney transplant patients did not improve kidney function, long-term proteinuria, or interstitial fibrosis.Clinical Trial registration numberNCT01602861.
KW - Adult
KW - Female
KW - Glomerular Filtration Rate/drug effects
KW - Humans
KW - Kidney Transplantation
KW - Kidney/physiopathology
KW - Male
KW - Middle Aged
KW - Mineralocorticoid Receptor Antagonists/therapeutic use
KW - Spironolactone/therapeutic use
KW - Treatment Outcome
KW - cyclosporine nephrotoxicity
KW - aldosterone
KW - chronic allograft failure
KW - proteinuria
KW - tacrolimus
KW - kidney transplantation
KW - randomized controlled trials
KW - progression of renal failure
KW - albuminuria
KW - fibrosis
U2 - 10.2215/CJN.0000000000000439
DO - 10.2215/CJN.0000000000000439
M3 - Journal article
C2 - 38416033
SN - 1555-9041
VL - 19
SP - 755
EP - 766
JO - Clinical Journal of the American Society of Nephrology
JF - Clinical Journal of the American Society of Nephrology
IS - 6
ER -